• In late June 2026, BioLife Solutions, Inc. (NasdaqCM: BLFS) was added to multiple Russell value-oriented benchmarks, including the Russell 3000 Value, 2000 Value, 2500 Value, Small Cap Comp Value, Microcap Value, and 3000E Value indices.
• This broad inclusion across Russell indices can increase the company’s visibility and relevance to institutional investors and index-tracking funds that follow value-focused benchmarks.
• Next, we’ll examine how BioLife’s broad addition to Russell value indices may influence its existing investment narrative around cell and gene therapy.

AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

BioLife Solutions Investment Narrative Recap

To own BioLife Solutions, you need to believe in the long term demand for tools that support cell and gene therapies, from biopreservation media to cell processing. The broad addition to Russell value indices improves visibility but does not materially change the near term focus on converting embedded products in approved and clinical therapies into recurring revenue, or the key risk that a concentrated customer base and funding pressure in early stage CGT programs could still unsettle results.

The recent Q1 2026 update, with US$27.5 million in sales and a swing to a small net profit, is the most relevant context for this index news. It shows how higher throughput across BioLife’s installed base can flow into improving earnings at a time when increased index inclusion may draw more attention to whether the company can sustain that revenue momentum amid customer concentration and CGT funding risk.

Yet behind the broader index inclusion, a high reliance on the top 20 customers remains a risk investors should be aware of...

BioLife Solutions' narrative projects $161.3 million revenue and $33.2 million earnings by 2028.

Uncover how BioLife Solutions' forecasts yield a $32.44 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members see BioLife’s fair value between US$18.47 and US$33.68 across 3 independent views, underscoring how far opinions can spread. When you set those against BioLife’s reliance on a relatively small group of CGT customers for a large share of revenue, it is worth comparing several viewpoints before deciding how that concentration risk could affect the company’s performance over time.

Explore 3 other fair value estimates on BioLife Solutions - why the stock might be worth as much as 19% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your BioLife Solutions research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free BioLife Solutions research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BioLife Solutions' overall financial health at a glance.

No Opportunity In BioLife Solutions?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.